Provention Bio is a biotechnology business based in the US. Provention Bio shares (PRVB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $24.98 – the same closing value as a week prior. Provention Bio employs 174 staff and has a trailing 12-month revenue of around $12.9 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $24.98 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $19.10 |
| 200-day moving average | $10.15 |
| Wall St. target price | $23.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.52 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $24.98 from 2023-04-27
| 1 week (2024-09-23) | N/A |
|---|---|
| 1 month (2024-08-31) | N/A |
| 3 months (2024-06-30) | N/A |
| 6 months (2024-03-31) | N/A |
| 1 year (2023-09-30) | N/A |
|---|---|
| 2 years (2022-10-04) | 425.34% |
| 3 years (2021-10-04) | 297.14% |
| 5 years (2019-10-04) | 252.82% |
| Revenue TTM | $12.9 million |
|---|---|
| Gross profit TTM | $-63,421,000 |
| Return on assets TTM | -43.01% |
| Return on equity TTM | -97.66% |
| Profit margin | 0% |
| Book value | $1.39 |
| Market Capitalization | $2.4 billion |
TTM: trailing 12 months
We're not expecting Provention Bio to pay a dividend over the next 12 months.
Over the last 12 months, Provention Bio's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Provention Bio's is 2.4604. This would suggest that Provention Bio's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Provention Bio, Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co. , Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China.
Step 1: Open and fund your account, Step 2: Enable options trading, Step 3: Select and trade options, Step 4: Closing options trades.
Learn the basics of put options: what they are, how they work and a few examples.
Learn the basics of call options: what they are, how they work and examples.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
Check out the best-performing ETFs so far in 2024.
What to expect when you sign up for a Zacks Trade brokerage account.